We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NuPathe Named Emerging Life Sciences Company of the Year
News

NuPathe Named Emerging Life Sciences Company of the Year

NuPathe Named Emerging Life Sciences Company of the Year
News

NuPathe Named Emerging Life Sciences Company of the Year

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NuPathe Named Emerging Life Sciences Company of the Year"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NuPathe Inc. has announced that it received the Emerging Life Sciences Company of the Year Award at Wednesday night's Enterprise Awards hosted by the Greater Philadelphia Alliance for Capital and Technologies (PACT).

The Enterprise Awards is considered the most prestigious Life Sciences and Technology Awards program in the Greater Philadelphia region.

NuPathe was selected Emerging Life Sciences Company of the Year by a panel of leading Life Sciences CEOs, entrepreneurs, professionals, and investment bankers.

Amongst the reasons cited for the award include NuPathe's successful initial public offering of common stock in August 2010 in an extremely difficult financing environment and FDA's acceptance for filing of the company's NDA for its lead product candidate, a single-use transdermal sumatriptan patch for migraine.

"The Greater Philadelphia region boasts a wealth of outstanding life sciences companies, and being honored in this elite group is a testament to our business strategy and the amazing efforts of the NuPathe team," said Jane Hollingsworth, chief executive officer of NuPathe.

Hollingsworth continued, "As we prepare to commercialize our migraine patch, we are thrilled to be in a position to draw on the rich talent available in the region to deliver on our promise to address significant unmet patient needs in the neurosciences."

Advertisement